Mammography World Markets

NEW YORK, Jan. 10, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Mammography World Markets

http://www.reportlinker.com/p098222/Mammography-World-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging

Breast cancer is the most common type of cancer in women, affecting one in eight during their lives. Mammography is the most valuable method for detecting potentially cancerous anomalies in the breast. As such, the mammography equipment segment is poised for a major new phase of growth fueled by the availability of new technologies. Mammograms are images of the breast tissue produced from low radiation X-rays. The three types of mammography systems are: 1) analog systems, 2) computed tomography (CR) systems and 3) full-field digital mammography (FFDM). The analog systems are the conventional types, and they use X-ray films for capturing the breast images. The CR systems are also film-based, but are retrofitted with digital detectors. In FFDM, the X-ray film is replaced by solid-state detectors that convert X-rays into electrical signals. Digital tomosynthesis is a new technology with improved diagnostic capabilities over standard digital mammography. Moreover, scintimammography (nuclear medicine breast imaging) is an additional breast exam available.

This TriMark Publications report thoroughly reviews: 1) existing and emerging mammography technologies, 2) known risk factors for breast cancer, 3) breast cancer treatments and drugs, 4) types of mastectomy procedures, 5) breast reconstruction surgery, and 6) funding for breast cancer research. The study examines almost all of the companies known to be marketing, manufacturing or developing mammography equipment and breast cancer therapies in the world. Each company is discussed in extensive depth with a section on its history, product lines, business and marketing analysis, and a subjective commentary of the company's market position. Detailed tables and charts with sales forecasts and market share data are also included.

TABLE OF CONTENTS 1. Overview 9

1.1 Statement of Report 9

1.2 Scope of This Report 10

1.3 Methodology 10

1.4 Executive Summary 11

2. Breast Cancer: An Overview 142.1 Anatomy of a Normal Breast 142.1.1 Abnormalities in Breast 142.1.2 Selected Types of Breast Cancer 152.1.3 Non-Invasive Breast Cancers 152.1.4 Invasive Breast Cancers 162.1.5 Other Benign Structures Found in the Breast in Screening Mammography 192.1.6 Other Breast Anomalies Detected During Diagnostic Mammography 20

3. Global and Regional Data on Breast Cancer 22

3.1 Global Breast Cancer Statistics, 2012 22

3.1.1 The Leading 50 Countries in Breast Cancer Incidence 24

3.2 Breast Cancer Occurrence in the U.S. 25

3.2.1 Probability of U.S. Women for Being Diagnosed with Breast Cancer 25

3.2.2 Breast Cancer by Age in the U.S. 26

3.2.3 Breast Cancer by Age and Ethnicity in the U.S. 26

3.2.4 Geographic Differences in Breast Cancer Rates in the U.S. 27

3.2.5 Changing Trends in In Situ Breast Cancer 29

3.2.6 Changing Trends in Invasive Breast Cancer in the U.S. 29

3.2.7 Breast Cancer in the U.S. by Race and Ethnicity 30

3.2.8 Breast Cancer in the U.S. by Tumor Size 31

3.2.9 Breast Cancer Mortality Rate in the U.S. 34

3.2.10 Incidence and Mortality Trends in Men 34

3.2.11 Factors Influencing Breast Cancer Survival in the U.S. 35

3.2.12 Five-Year Relative Survival Rate in the U.S. by Stage at Diagnosis 35

3.2.13 Five-Year Survival Rate by Race/Ethnicity and Socioeconomic Factors in the U.S. 36

3.2.14 Five-Year Cause-Specific Survival Rate in the U.S. by Race/Ethnicity 37

3.3 Breast Cancer in Canada 38

3.3.1 Breast Cancer Incidence in Canada by Age, 2012 39

3.3.2 Breast Cancer Mortality in Canada 40

3.3.3 Incidence and Mortality Rates for Breast Cancer in Canadian Women 40

3.3.4 The Five-Year Relative Survival Ratio in Canada 41

3.3.5 Age-Standardized Incidence Rates of Ductal and Lobular Breast Cancer in Canada 42

3.4 Breast Cancer in the U.K. 42

3.4.1 Breast Cancer by Age in the U.K. 43

3.5 Breast Cancer Mortality in OECD Countries 44

3.5.1 Relative Survival Rates from Breast Cancer in OECD Countries 46

3.6 Breast Cancer in Australia 47

3.6.1 Incidence of Breast Cancer by Age in Australia 47

3.6.2 Projected Female Breast Cancer Diagnosis in Australia, 2020 49

3.6.3 Risk of Being Diagnosed with Breast Cancer in Australia 50

3.6.4 Most Common Types of Breast Cancers in Australia 50

3.6.5 Age at Diagnosis by Histological Type in Australia 51

3.6.6 Most Frequently Recorded Anatomical Location of Breast Cancer 51

3.6.7 Ductal Carcinoma In Situ in Australia 52

3.6.8 Incidence of DCIS by Age in Australian Women 53

3.6.9 Female Breast Cancer Mortality in Australia by Age 53

3.6.10 Projections of Female Breast Cancer Mortality in Australia 54

3.6.11 Survival after Diagnosis of Female Breast Cancer in Australia 55

3.6.12 Hospitalizations for Female Breast Cancer in Australia 55

3.7 Breast Cancer in East Asia 56

3.8 Breast Cancer in Western Asia 56

3.9 Breast Cancer Mortality in Korea 57

3.10 Age-Specific Incidence of Breast Cancer in Japan 58

3.11 Age-Specific Breast Cancer Rate in China 58

3.12 Breast Cancer in Young Asian Women 59

4. Emerging Technologies in Breast Imaging 604.1 The Gold Standard: Full-Field Digital Mammography 604.2 Tomosynthesis/3-D Mammography 624.3 Molecular Imaging 634.4 BSGI 63

5. Mammography: An Overview 66

5.1 Screen-Film Mammography 66

5.2 2D Digital Mammography 67

5.3 3D Digital Mammography 68

5.3.1 Better Visualization in 3D Images 70

5.3.1.1 3D Imaging and Superimposed Breast Tissue 71

5.3.1.2 Status of Tomosynthesis 72

5.3.1.3 Other Companies Working on Digital Breast Tomosynthesis (DBT) 73

5.3.1.4 Features of Hologic Tomosynthesis Unit 73

5.3.1.5 GE Tomosynthesis 73

5.3.1.6 Siemens Tomosynthesis 73

5.3.1.7 Philips (Sectra) Tomosynthesis 73

5.3.2 Difference between 3D and 2D Digital Mammography 74

5.3.2.1 Comparative Merits of Digital and Film-Screen Mammography 74

5.4 Basic Physics of Mammography 75

5.4.1 Mammography X-Ray Tubes 75

5.4.2 Mammography Image Receptors 77

5.4.3 Mammography AEC 79

5.4.4 Mammography Scatter Reduction 79

5.4.5 Differences in Dose Levels among Digital Mammography Systems 79

5.4.6 The Irish Study 79

5.4.7 Patient Radiation Doses in Swedish Screening Program 80

5.5 Points to be Considered Before Buying a Mammography System 81

5.6 Cost Containment in Mammography Systems 82

6. Screening Mammography Data from Selected Countries 846.1 U.S. Data on Screening Mammography 846.1.1 Prevalence of Mammography in the U.S. 846.1.2 Drop in U.S. Mammography Rates 846.1.3 Guidelines for Screening Mammography in the U.S. 856.1.4 Crisis in U.S. Mammography Services 856.1.5 Current Mammography Use in the U.S. 876.2 Organized Screening Programs in Canada 896.2.1 Early Detection of Breast Cancer in Canada 896.2.2 Distribution of Breast Cancer Detected during Screening by Stage in Canada 916.2.3 Newly Diagnosed Women with Her2+ by Province in Canada 916.2.4 Breast Cancer Treatment after Diagnosis in Canada 926.2.5 Radiation Therapy after Diagnosis in Canada 936.2.6 Chemotherapy after Breast Cancer Screening in Canada 936.2.7 Screening Mammography in British Colombia (BC) 946.2.7.1 Annual Screening Volume in BC 946.2.7.2 Bilateral Mammography Utilization in BC 966.2.7.3 Histologic Features of Breast Cancers Detected by SMP in BC 966.3 European Data on Screening Mammography 966.3.1 Screening Mammography Rates in OECD Countries 1006.3.2 Screening Mammography in the U.K. 1026.3.3 Screening Activity in the U.K. 1026.3.4 Acceptance of Screening Invitation by Age—All Invitation Types in the U.K. 1026.3.5 Acceptance by Type of Screen in the U.K. 1036.3.6 Screening Quality—First Screen after First Invitation in the U.K. 1036.3.7 Screening Quality—Subsequent Screening in the U.K. 1036.3.8 Screening—Women Aged 71 and Over in the U.K. 1046.3.9 Assessment Outcomes—Age 50-70 in the U.K. 1046.3.10 Assessment Outcomes—Age 45-74 in the U.K. 1056.3.11 Treatment of Screen Detected Breast Cancer in the U.K. 1056.3.12 Immediate Reconstruction after Mastectomy in the U.K. 1066.4 Screening Mammography in Korea 1076.5 Screening Mammography in Japan 1076.6 National Mammography Screening Program in Israel, 2010 1086.7 Mammography in Australia 1096.7.1 MBS-Funded Mammography in 2011 1106.7.2 Differences in Mammography Services by Age in Australia 1116.7.3 Hospitalizations for Female Breast Cancer in Australia 1116.7.4 Most Commonly Undertaken Female Breast Cancer Procedures in Australia 112

7. Mammography: Market Analysis 113

7.1 Global Market for Mammography Equipment 113

7.1.1 Global Market for Full-Field Digital Mammography Systems 114

7.1.2 Leading Vendors in Mammography Sector 115

7.2 U.S. Market for Full-Field Digital Mammography 115

7.2.1 Decline in the Number of Mammography Facilities and Units in the U.S. 116

7.2.2 Growth in Number of Digital Mammography Facilities in the U.S. 117

7.3 Rest of the World Market for Digital Mammography 118

7.4 Mammography Systems Market in Europe 119

8. Profiles of Market Leaders in Mammography 1218.1 Fujifilm U.S.A., Inc. 1218.1.1 Amulet f/Amulet s 1218.1.2 Fuji's 3D Mammography Viewer 1218.2 GE Healthcare Ltd. 1228.2.1 SenoBright 1228.2.2 Senographe Essential 1228.2.3 Senographe Essential e 1238.2.4 Senographe Care 1238.2.5 Senographe DS 1248.2.6 GE's Mammography Workstations 1248.3 Hologic, Inc. 1248.3.1 Selenia Dimension 3D 1258.3.2 Selenia Dimensions 2D 1258.3.3 SecurView 1268.3.4 SecurXchange Archiving Solution 1268.3.5 M-Series (Analog) 1268.3.5.1 StereoLoc 1268.3.5.2 Affinity 1278.4 Philips Healthcare 1278.4.1 MammoDiagnost (Analog) 1278.4.2 MammDiagnost DR 1288.4.3 MammoDiagnost with PCR Eleva 1288.5 Siemens Healthcare 1288.5.1 Mammomat 3000 Nova 1298.5.2 Mammomat 1000 1298.5.3 Syngo MammoReport 129

Appendix 1: Timeline of Advances Against Breast Cancer 130

Appendix 1.1: Timeline 130

Appendix 2: A Woman's Guide to Breast Cancer 138

Appendix 2.1: Breast Biopsy 138

Appendix 2.2: Staging of Breast Cancer 139

Appendix 2.3: Treatment Options 141

Appendix 3: A Women's Guide to Mammograms 146

Appendix 4: A Voice against Screening Mammography 151

Appendix 5: Performance of Tomosynthesis in Different Breast Compositions and Lesion Types 153

Appendix 5.1: Improved Sensitivity 154

Appendix 5.2: Reduced Recall Rate 154

Appendix 5.3: Greater Performance Using Two-View Tomosynthesis 155

Appendix 5.4: Performance of Tomosynthesis in Different Breast Compositions and Lesion Types 155

Appendix 5.5: Performance in Calcifications, Masses and Distortions 155

Appendix 5.6: Performance in Invasive and Non-Invasive Breast Cancers 156

Appendix 5.7: Performance in Fatty and Dense Breasts 156

Appendix 5.8: Tomosynthesis Compared to Ultrasound 157

Appendix 5.9: Tomosynthesis Performance in the Evaluation of Symptomatic Patients 157

Appendix 5.10: Clinical Considerations in Implementing Tomosynthesis 158

Appendix 5.11: One-View vs. Two-View Tomosynthesis 158

Appendix 5.12: Benefits of Combo-Mode Imaging 159

Appendix 5.13: Patient Dose and Risk/Benefit 159

Appendix 6: Cancer Treatment and Survivorship 160

Appendix 6.1: Female Breast Cancer 162

Appendix 6.1.1: Treatment and Survival after Breast Cancer 163

Appendix 6.1.2: Special Concerns of Breast Cancer Survivors 165

Appendix 6.2: Childhood Cancer 165

Appendix 6.3: Colon and Rectum Cancer 166

Appendix 6.4: Leukemias and Lymphomas 169

Appendix 6.5: Lung and Bronchus Cancer 173

Appendix 6.6: Melanoma 175

Appendix 6.7: Prostate Cancer 177

Appendix 6.8: Testicular Cancer 179

Appendix 6.9: Thyroid Cancer 182

Appendix 6.10: Urinary Bladder Cancer 183

Appendix 6.11: Uterine Corpus 185

Appendix 6.12: Challenges for Newly Diagnosed Cancer Patients 187

Appendix 7: U.S. Spending on Cancer 201

Appendix 8: Reimbursement for Screening and Diagnostic Mammography in the U.S. 205

Appendix 8.1: Reimbursement Guidelines for Screening and Diagnostic Mammography 205

Appendix 8.2: Codes and Payment Rates 206

Appendix 8.3: Reimbursement Guidelines for Diagnostic MRI Imaging 207

Appendix 9: Integration of Digital Mammography on PACS 209

Appendix 9.1: Considerations in Deploying Digital Mammography 209

INDEX OF FIGURES Figure 3.1: Breast Cancer Incidence Worldwide 22

Figure 3.2: Lifetime Risk of Breast Cancer Worldwide 23

Figure 3.3: Age-Specific Female Breast Cancer Incidence and Mortality Rates in the U.S. 26

Figure 3.4: Female Breast Cancer Incidence and Mortality Rates by Race and Ethnicity in the U.S. 27

Figure 3.5: Incidence Rates of In Situ Breast Cancer by Age in the U.S., 1975-2008 29

Figure 3.6: Incidence Rates of Invasive Breast Cancer by Age, 1975-2008 30

Figure 3.7: Breast Cancer in the U.S. by Race and Ethnicity, 1975-2008 31

Figure 3.8: Breast Cancer Incidence Rates by Tumor Size (=2.0 cm) and Race, 1989-2008 32

Figure 3.9: Localized Breast Cancer Rates in the U.S. by Race, 1976-2008 32

Figure 3.10: Breast Cancer Rate (Tumor Size = 2.1-5.0 cm) in the U.S., 1989-2008 33

Figure 3.11: Breast Cancer Rate (Regional Stage) in the U.S., 1976-2008 33

Figure 3.12: Breast Cancer Death Rate in the U.S. by Race and Ethnicity, 1975-2007 34

Figure 3.13: Trend in Male Breast Cancer Incidence and Mortality in the U.S., 1975-2008 35

Figure 3.14: Five-Year Relative Survival Rate by Stage at Diagnosis and Race 36

Figure 3.15: Breast Cancer Five-Year Relative Survival Rate by Race, 1975-2007 37

Figure 3.16: Percent of All Estimated Cancer Cases in Canadian Women, 2012 39

Figure 3.17: Age-Standardized Incidence and Mortality Rates of Breast Cancer in Canada, 1992-2007 41

Figure 3.18: Five-Year Relative Survival for Breast Cancer by Age Group in Canada, 2005 and 2007 41

Figure 3.19: Age-Standardized Incidence Rates of Ductal and Lobular Cancer in Canada, 1992-2007 42

Figure 3.20: Number of New Breast Cancer Cases per Year and AS Rate in the U.K., 2009 44

Figure 3.21: Female Breast Cancer Mortality Rate in OECD Countries, 2000 and 2009 45

Figure 3.22: Breast Cancer Five Year Relative Survival Rate in OECD Countries, 1997-2009 46

Figure 3.23: Incidence of Breast Cancer by Age at Diagnosis, Females, Australia, 2008 47

Figure 3.24: Incidence of Female Breast Cancer in Australia, 1982-2008 48

Figure 3.25: Incidence of Female Breast Cancer by Age at Diagnosis in Australia, 1982-2008 49

Figure 3.26: Incidence of Female Breast Cancer in Australia, 2000-2020 49

Figure 3.27: Incidence of Ductal Carcinoma In Situ in Australia, 2000-2008 52

Figure 3.28: Incidence of Ductal Carcinoma by Age in Australian Women, 1997-2008 53

Figure 3.29: Female Breast Cancer Incidence and Mortality in Australia by Age, 2008 54

Figure 3.30: Projected Mortality from Female Breast Cancer in Australia, 2000-2020 54

Figure 3.31: Incidence of Breast Cancer in East Asia 56

Figure 3.32: Incidence of Breast Cancer in Western Asia 57

Figure 3.33: Breast Cancer Mortality in Korea, 1985-2020 57

Figure 3.34: Age-Specific Incidence of Breast Cancer in Japan 58

Figure 3.35: Age-Specific Breast Cancer Incidence Rate in China 59

Figure 5.1: Tissue Superimposition Hiding Pathologies in 2D 69

Figure 5.2: Minimizing the Effects of Structure Overlapping within the Breast by 3D 69

Figure 5.3: Schematic of Tomosynthesis 70

Figure 5.4: A Suspicious Area in the 2D Mammography Image 70

Figure 5.5: The 2D Image Next to One Slice of 3D Image Set Showing a Clear Difference 71

Figure 5.6: A 2D Image with a Suspicious Area, Next to a 3D Image Set 71

Figure 5.7: Another 3D Image from the Set Showing that the Suspicious Area is Nothing More than Normal Breast Structures Overlapping 72

Figure 5.8: Detection of Micro-Papillary Type Ductal Carcinoma In Situ in 65 Year Old Woman by 3D 72

Figure 5.9: Comparison of Digital and Film-Screen Breast Images 75

Figure 5.10: X-Ray Energy Spectra for (a) a Mo Anode XRT and (b) with the Addition of 30 µm Thickness of Mo Filtration 76

Figure 5.11: A Mammographic XRT with Collimation and Breast Support 76

Figure 5.12: (a) A Large Phosphor Screen Coupled to Several OCDs Using Fiber

Optic Tapers (b) A Scanning-Slot System Where a Narrow Phosphor Screen is

Coupled by the Fiber Optics to a Few CCDs and the XRT/Detector is Scanned Across the Anatomy 77

Figure 5.13: Illustration of Scanned-Slot Digital Mammography 78

Figure 5.14: The Average MGD per Exposure for Different Models of FFDM in both Screening and Clinical Mammography 81

Figure 6.1: U.S. Mammography Units and Facilities, 2000-2011 86

Figure 6.2: Mammography Use Among Women 40 Years of Age and Over by Age in the U.S., 2000-2010 87

Figure 6.3: Percentage of Women (Aged 50-69) Who Participated in an Organized Program in the Past Two Years by Province, 2009-2010 89

Figure 6.4: Distribution by Stage at Diagnosis of Women Diagnosed with Invasive Breast Cancer in Canada by Province, 2010 90

Figure 6.5: Distribution by Stage at Diagnosis of Women Diagnosed with Breast Cancer in Canada, 2010 91

Figure 6.6: Percentage of Women Tested as Her2+ by Province in Canada, 2010 91

Figure 6.7: Percentage of Mastectomies by Province in Canada, 2009-2010 92

Figure 6.8: Percentage of Breast Cancer Patients Receiving Radiation Therapy, Started Within Two Years of Diagnosis by Province in Canada, 2009 93

Figure 6.9: Percentage of Breast Cancer Patients Receiving Chemotherapy Started Within One Year of Diagnosis by Province in Canada, 2009 94

Figure 6.10: SMP Annual Screening Volume in BC, 2006-2010 95

Figure 6.11: Bilateral Utilization of Mammography by Women Ages 50-69, 2008-2010 95

Figure 6.12: Breast Cancer Screening at Least Once in Life in Europe (Age 50 to 69), 2010 97

Figure 6.13: Breast Cancer Screening at Least Once in Life in Europe (Age 50), 2010 97

Figure 6.14: Proportion of European Women having Undergone Breast Cancer

Screening by Frequency, 2010 98

Figure 6.15: European Participation in Mammography Screening by National Program and Other, 2010 99

Figure 6.16: European Participation in Breast Cancer Screening (Age 50-69) by Educational Status, 2010 99

Figure 6.17: European Participation in Breast Cancer Screening by Income Quintile, 2010 100

Figure 6.18: Percentage of Women Aged 50 to 69 Screened in OECD Countries, 2000-2009 101

Figure 6.19: Treatment of Screen Detected In Situ Non-Invasive and Micro-Invasive Breast Cancer in the U.K. 105

Figure 6.20: Treatment of Screen Detected Invasive Breast Cancer in the U.K. 106

Figure 6.21: Reconstruction after Mastectomy in the U.K., 2009-2010 106

Figure 6.22: Breast Cancer Screening Rates in Korea, 2004-2007 107

Figure 6.23: Participation in Breast Cancer Screening by Age in Japan, 2007 108

Figure 6.24: Participation in BreastScreen Australia by Women Aged 50-69, 2000-2010 110

Figure 6.25: MBS-Funded Mammography Services by Age Group in Australian Women, 2011 111

Figure 7.1: Global Market for Mammography Systems, 2011-2018 113

Figure 7.2: Global Market for FFDM Mammography Equipment, 2011-2018 114

Figure 7.3: Global Market Leaders in Mammography Equipment Market, 2011 115

Figure 7.4: U.S. Market for Full-Field Digital Mammography Market, 2011-2018 116

Figure 7.5: U.S. Mammography Units and Facilities, 2000-2011 117

Figure 7.6: Growth in Number of FFDM Units and Facilities in the U.S., 2004-2010 118

Figure 7.7: Rest of the World Market for Mammography Equipment, 2011-2018 119

Figure 7.8: European Market for Mammography System, 2011-2018 120

Figure A2.1: Tumor Sizes 140

Figure A5.1: Improvement in Cancer Detection 154

Figure A5.2: Increased Breast Cancer Detection Using Tomosynthesis 155

Figure A5.3: Reduced Recall Rates 155

Figure A5.4: Added Value for Calcifications 156

Figure A5.5: Value of Tomosynthesis in Fatty Breasts 157

Figure A5.6: Greater Perception of Extent of Disease Using Tomosynthesis 158

Figure A5.7: Two-View Tomosynthesis Optimizes Chance for Cancer Detection 158

Figure A5.8: Dose Levels of 2D and Tomo Exams Compared to Natural Background Radiation 159

Figure A6.1: Breast Cancer in the U.S. by Race and Stage at Diagnosis 162

Figure A6.2: Female Breast Cancer Treatment Patterns by Stage 163

Figure A6.3: Five-Year Survival Rates for Breast Cancer Patients by Race and Stage at Diagnosis 164

Figure A6.4: Distribution of Colon and Rectum Cancer by Race and Stage at Diagnosis 167

Figure A6.5: Colon Cancer Treatment Patterns by Stage 167

Figure A6.6: Rectal Cancer Treatment Patterns by Stage 168

Figure A6.7: Five-Year Survival Rates for Colon and Rectal Cancer Patients by Race and Stage at Diagnosis 169

Figure A6.8: Distribution (%) of Non-Hodgkin Lymphoma Patients by Race and Stage at Diagnosis 170

Figure A6.9: Chemotherapy Use among Leukemia Patients by Age 171

Figure A6.10: Non-Hodgkin Lymphoma Treatment Patterns 172

Figure A6.11: Distribution (%) of Lung and Bronchus Cancer by Race and Stage at Diagnosis 173

Figure A6.12: Non-Small Cell Lung Cancer Treatment Patterns by Stage 174

Figure A6.13: Five-Year Survival Rates for Lung and Bronchus Cancer Patients by Race and Stage 175

Figure A6.14: Distribution (%) of Melanoma by Race and Stage 175

Figure A6.15: Five-Year Survival Rates for Melanoma Patients by Race and Stage 176

Figure A6.16: Distribution of Prostate Cancer by Race and Stage 177

Figure A6.17: Prostate Cancer Primary Treatment Patterns by Age 178

Figure A6.18: Five-Year Survival Rates for Prostate Patients by Race and Stage 179

Figure A6.19: Distribution of Testicular Cancer by Race and Stage 179

Figure A6.20: Treatment Patterns for Testicular Cancer Patients 180

Figure A6.21: Treatment Patterns for Non-Seminomatous Testicular Cancer 181

Figure A6.22: Five-Year Survival Rates for Testicular Cancer Patients by Race and Stage 181

Figure A6.23: Distribution of Thyroid Cancer by Race and Stage 182

Figure A6.24: Five-Year Survival Rates for Thyroid Cancer Patients by Race and Stage 183

Figure A6.25: Distribution of Urinary Bladder Cancer by Race and Stage 184

Figure A6.26: Muscle Invasive Bladder Cancer Treatment Patterns 184

Figure A6.27: Five-Year Survival Rates for Urinary Bladder Cancer Patients by Race and Stage 185

Figure A6.28: Distribution of Uterine Corpus Cancer by Race and Stage 186

Figure A6.29: Uterine Cancer Treatment Patterns by Stage 186

Figure A6.30: Five-Year Survival Rates for Uterine Corpus Cancer Patients by Race and Stage 187

Figure A6.31: Domains of Quality of Life 193

Figure A6.32: Observed-to-Expected Ratios for Subsequent Cancers by Site, Sex

and Age 20 and Older 196

Figure A6.33: Observed-to-Expected Ratios for Subsequent Cancers by Primary Site 198

Figure A6.34: Unmet Caregiver Needs by Time Since Diagnosis 199

Figure A7.1: Estimates of National Expenditures for Cancer Care in 2010 by Site 201

Figure A7.2: National Expenditure for Cancer Care in 2010 by Site and Phase of Care 202

Figure A7.3: Proportion of National Expenditure for Cancer Care in 2010 by Site and Phase of Care 203

Figure A7.4: Percentage of Medicare Payments in the First Year Following Diagnosis for Cancer Care by Type of Service in 2002 204

Figure A9.1: Workflow Using Philips' iSite Radiology for Mammography SCR 210

Figure A9.2: Workflow Using Third Party Workstation for Mammography SCR 211

INDEX OF TABLES Table 3.1: The Top 50 Countries with Leading Breast Cancer Rates 24

Table 3.2: Estimated New Female Breast Cancer Cases and Death by Age in the U.S., 2011 25

Table 3.3: Probability of U.S. Women fore Being Diagnosed with Breast Cancer 25

Table 3.4: Female Breast Cancer Incidence and Mortality Rates by Race, Ethnicity and State 28

Table 3.5: Five-Year Cause-Specific Survival Rate by Race/Ethnicity 38

Table 3.6: New Breast Cancer Cases Diagnosed in Canadian Women, 2012 39

Table 3.7: New Breast Cancer Cases Diagnosed in Canada by Age Group, 2012 39

Table 3.8: Breast Cancer Mortality Rates in Canada, 2012 40

Table 3.9: Breast Cancer Incidence Rates per 100,000 Populations in the U.K., 2009 43

Table 3.10: Number of Breast Cancer Patients in the U.K., 2009-2010 43

Table 3.11: The Five Most Commonly Diagnosed Cancers, Females, Australia, 2008 47

Table 3.12: Risk and Average Age at Diagnosis of Female Breast Cancer in Australia, 1982-2008 50

Table 3.13: Incidence and Average Age at diagnosis by Type of Breast Cancer in Australia, 2008 51

Table 3.14: Incidence by Histological Type and Age at Diagnosis in Australia, 2008 51

Table 3.15: Incidence of Breast Cancer by Anatomical Location in Australia, 2008 52

Table 3.16: Relative Survival from Female Breast Cancer in Australia, 2006-2010 55

Table 3.17: Hospitalization for Female Breast Cancer in Australia, 2009-2010 55

Table 3.18: Breast Cancer in Asian Younger Women 59

Table 5.1: DR System Comparisons 68

Table 5.2: Average Mean Glandular Dose per Exposure According to Model 80

Table 5.3: Examination Dose According to Model 80

Table 5.4: Average MGD per Exposure in Screening and Clinical Use for Various Mammography Technologies and Vendors of FFDM 81

Table 6.1: Mammography Screening Prevalence Among Women 40 and Older in the U.S., 2010 84

Table 6.2: Mammography Screening Prevalence by Age and Poverty Status in the U.S., 1987-2010 85

Table 6.3: Certified Mammography Facilities and Accredited Units in the U.S., 2000-2011 86

Table 6.4: Prevalence of Screening Mammography in the U.S. by State, 2010 87

Table 6.5: Histologic Features of Breast Cancers Detected by SMP in BC, 2009 96

Table 6.6: Breast Cancer Screening Activity in the U.K., 2008-2010 102

Table 6.7: Acceptance of Breast Screening Invitations by Age—All Invitation Types 102

Table 6.8: Acceptance by Type of Screen: Women Aged 45-74 103

Table 6.9: Screening Quality—First Screen after First Invitation 103

Table 6.10: Screening Quality—Subsequent Screening 104

Table 6.11: Screening—Women Aged 71 and Over in the U.K. 104

Table 6.12: Assessment Outcomes—Age 50-70 104

Table 6.13: Assessment Outcomes—Age 45-74 in the U.K. 105

Table 6.14: Medicare Benefits Schedule-Funded Mammography Services in Australia, 2011 110

Table 6.15: Hospitalization for Female Breast Cancer in Australia, 2009-2010 111

Table 6.16: Same-Day Hospitalizations and Overnight Hospitalizations for Female Breast Cancer in Australia, 2009-2010 112

Table 7.1: Certified Mammography Facilities and Accredited Units in the U.S., 2000-2011 117

Table A2.1: Staging of Breast Cancer 139

Table A6.1: Estimated Number of Cancer Survivors in the U.S. as of January 1, 2012 160

Table A6.2: Estimated Numbers of U.S. Cancer Survivors by Site as of January 1, 2012 161

Table A6.3: Estimated U.S. Cancer Survivors by Sex and Time since Diagnosis as of January 1, 2012 161

Table A6.4: Estimated U.S. Cancer Survivors by Sex and Age as of January 1, 2012 162

Table A8.1: Mammography Reimbursement Rates—All Sites of Services 206

Table A8.2: Reimbursement for Breast MRI—Hospital Outpatient 207

Table A8.3: Reimbursement for MRI Breast Imaging—Offices and Imaging Centers/Physician 208

To order this report:Medical_Imaging Industry: Mammography World Markets

Contact
Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

 

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.